Immune · Reference
Thymalin Benefits: What the Research Actually Shows
This page goes benefit by benefit, names the kind of study behind each finding and its limits, then covers how thymalin differs from thymosin alpha-1, side effects, FDA status and how Pepti supplies it. For the full product reference, see what is thymalin.
Treatments mentioned
Thymalin is a calf-thymus peptide extract developed in Russia in the 1970s, and the benefits claimed for it, stronger T-cell function, calmer inflammatory signalling, fewer respiratory infections and healthier ageing, rest on cell studies and Russian observational and hospital reports, not on randomized controlled trials. The largest body of human work followed 266 older adults over six to eight years and reported fewer respiratory illnesses and lower mortality in thymalin-treated groups, but its published abstracts describe no randomization, blinding or placebo, and no independent group has replicated it. There is no Western trial of thymalin. Every benefit below is something research has looked at, not something an injection can promise.
This page goes benefit by benefit, names the kind of study behind each finding and its limits, then covers how thymalin differs from thymosin alpha-1, side effects, FDA status and how Pepti supplies it. For the full product reference, see what is thymalin.
Thymalin Benefits
The short answer
| Claimed benefit | What the evidence is | Strength of evidence |
|---|---|---|
| T-cell maturation | Cell (human blood stem cells in culture, 2020) | Cell only |
| Calmer inflammatory signalling | Cell (human immune cells and a monocyte line, 2022 and 2023) | Cell only |
| Immune ageing in older adults | Human (Russian observational programme, 2002 and 2003) | Long-running, but no randomization, blinding or placebo described |
| Fewer respiratory infections | Human (same programme) | Reported, not tested in a controlled design |
| Longevity | Human (same programme) | Reported, not tested in a controlled design |
| Inflammation and clotting markers in hospital patients | Human (two Russian COVID-19 hospital studies, 2021 and 2022) | Observational; group sizes not given in the abstracts |
| Respiratory conditions and other Russian indications | Statements by the developing group | Not established in published controlled studies |
Pepti supplies Thymalin as a 5 mL vial at 1 mg/mL (5 mg per vial) for $209/mo, all-in.
Thymalin Benefits
What thymalin is, briefly
Thymalin is a polypeptide complex, a mixture of short peptides, extracted from the thymus gland of young cattle. That separates it from most peptides on this site, which are single defined sequences a chemist can synthesize. The group that developed it describes two dipeptides inside the mixture, Lys-Glu (KE) and Glu-Trp (EW), as the active components.
The thymus is where T-lymphocytes mature. It is large in childhood and shrinks steadily from puberty onward, and the loss of thymic output is one of the best-described contributors to the weakening of the immune system in older age. The rationale for thymalin is to supply thymic signalling peptides to a body whose own thymus has largely stopped producing them. It was developed by Vladimir Khavinson and Vyacheslav Morozov from 1973 onward at what became the St. Petersburg Institute of Bioregulation and Gerontology, and it has been used clinically in Russia for decades.
That provenance shapes everything below. Almost all of the literature comes from one research group and its collaborators, much of it in Russian-language journals, and the study designs described are not the randomized, blinded trials Western regulators require. That does not make the work wrong. It means it should be read as what it is.
Thymalin Benefits
Benefit by benefit
1. T-cell maturation
What the research describes. A 2020 paper in the Bulletin of Experimental Biology and Medicine exposed human hematopoietic stem cells, the bone-marrow cells that give rise to every blood cell, to thymalin in culture. It reported expression of CD44 and CD117, markers of stem cells and of an intermediate stage, falling two to three times, and CD28, a marker of mature T-lymphocytes, rising nearly seven times. The authors read this as thymalin nudging progenitor cells toward mature T-cells.
What it does not show. It is a cell-culture finding, and the paper says the molecular mechanism still requires study. It does not establish that the same thing happens in people, or at the doses used in people.
2. Calmer inflammatory signalling
What the research describes. The developing group's 2023 paper in the International Journal of Molecular Sciences tested thymalin and its two dipeptides on human blood immune cells stimulated with bacterial lipopolysaccharide, and reported that synthesis of the inflammatory cytokines IL-1 beta, IL-6 and TNF-alpha fell by 1.4 to 6 times. Molecular modelling described the dipeptides binding short DNA sequences linked to the AKT1 and AKT2 proteins in cytokine signalling. A 2022 study in the same journal, run in Italy with the St. Petersburg group as co-authors, tested thymalin alongside four other Khavinson peptides on a human monocyte cell line; all five reduced TNF and IL-6 and reduced the cells' adhesion to activated blood vessel cells, an early step of inflammation.
What it does not show. Both are cells in a dish, and the mechanism work outside Russia was co-authored with the developing group. If inflammation that will not settle is the concern, rather than a weakened immune response, KPV is described around inflammatory pathways more directly; see KPV benefits.
3. Immune ageing in older adults
What the research describes. The foundational human work is a long observational programme reported in Advances in Gerontology in 2002 and, in English, in Neuroendocrinology Letters in 2003. Researchers in St. Petersburg and Kiev followed 266 elderly and older people over six to eight years, treating them with thymalin, with the pineal extract Epithalamin, or with both, for the first two to three years, and compared them with controls. The papers report improvements across cardiovascular, endocrine, immune and nervous system measures. Courses were repeated annually.
What it does not show. The abstracts do not describe randomization, blinding or placebo, and the work has not been replicated by an independent group. It is the largest and longest body of human experience with thymalin and the reason it is discussed for age-related immune decline; it is not a trial in the sense a regulator would use the word.
4. Fewer respiratory infections
What the research describes. The same programme reported a 2.0 to 2.4-fold reduction in the incidence of acute respiratory disease in treated groups compared with controls.
What it does not show. Without randomization or a placebo, the comparison cannot separate thymalin from differences between the groups. No controlled trial has tested whether thymalin reduces infections. It is not an antibiotic or an antiviral and does not treat an infection directly.
5. Longevity
What the research describes. The programme reported mortality over the observation period 2.0 to 2.1 times lower in the thymalin group than in controls, with larger differences for thymalin combined with Epithalamin. That combination is why thymalin is often discussed alongside Epithalon, the synthetic tetrapeptide derived from Epithalamin; see Epithalon benefits.
What it does not show. These are striking numbers from an uncontrolled design. They do not establish that thymalin extends life in anyone, and they have never been tested in a randomized trial.
6. Inflammation and clotting markers in hospital patients
What the research describes. The most recent human reports come from Russian COVID-19 wards. A 2021 paper in Stem Cell Reviews and Reports reported that patients given thymalin alongside standard treatment showed a faster fall in IL-6, C-reactive protein and D-dimer than controls on standard treatment alone. A 2022 paper in Advances in Gerontology, in middle-aged and elderly patients with severe disease, described higher lymphocyte and monocyte counts and lower fibrinogen, lactate dehydrogenase and D-dimer in the thymalin group, and reported lower in-hospital mortality than standard care.
What it does not show. Neither abstract describes randomization or blinding, group sizes are not given, and the 2022 paper's English and Russian abstracts report slightly different mortality figures, which is why no percentage is quoted here. This is pandemic-era clinical experience in one country's health system, not a randomized trial. Thymalin is not a treatment for COVID-19 or any infection, and an active infection is a question for your physician.
7. Respiratory conditions and other Russian indications
What the research describes. The St. Petersburg group's papers state that thymalin has been used in the therapy of acute respiratory distress syndrome, chronic obstructive bronchitis and other immune conditions.
What it does not show. Those statements reflect its clinical use in Russia, reported by the developers, rather than published controlled studies that can be examined. Thymalin also appears in some animal work, a 2018 rat study and 2024 Ukrainian papers on jaw-bone defects in rats, which is peripheral and not support for any use.
Thymalin Benefits
What the evidence shows, honestly
| What the evidence has | What it lacks |
|---|---|
| Decades of clinical use in Russia | Any randomized controlled trial |
| A 266-person, six-to-eight-year observational programme | Randomization, blinding, placebo and independent replication |
| Cell studies of T-cell maturation and cytokine output | Evidence those effects occur at the doses used in people |
| Two hospital studies with blood-marker changes | Group sizes in the abstracts, and controlled outcomes |
| A reported clean tolerability record | Long-term safety under modern pharmacovigilance |
There are no randomized controlled trials of thymalin. The honest framing is "used clinically in Russia for decades, with mechanistic support from cell studies, and without controlled trials." Any source describing it as proven is overstating it. Research does not establish an effect size or a timeline in any population, because no trial has measured one.
Thymalin Benefits
Thymalin vs thymosin alpha-1
These are the two thymic immune peptides Pepti supplies, and they are not the same thing under two names.
| Thymalin | Thymosin alpha-1 | |
|---|---|---|
| What it is | A natural polypeptide extract of calf thymus | A single 28-amino-acid synthetic sequence |
| Where it came from | Leningrad, 1970s | First isolated from a thymic fraction in the US, 1970s |
| Human evidence | Russian observational and hospital reports; no randomized trials | International randomized trials, including hepatitis B, vaccine response and sepsis |
| Approval status | Not approved in the United States | A branded version is approved in a number of countries outside the US; compounded versions are not FDA approved |
| Pepti product | Thymalin, $209/mo | Thymosin Alpha-1, $249/mo |
If the controlled-evidence file is what matters most, thymosin alpha-1 is the stronger one; see thymosin alpha-1 benefits. Thymalin is the one discussed when the interest is specifically the Russian geroprotective programme and the whole-extract approach. The FORTIFY Blend ($289/mo) is built around thymosin alpha-1, not thymalin. The wider picture is in peptides for immune support.
Thymalin Benefits
Thymalin side effects
Thymalin has been given to people in Russia for decades, and the published clinical reports do not describe a characteristic toxicity.
| What is reported | What to do |
|---|---|
| Injection-site redness, mild soreness, occasional bruising or itching | Rotate sites between abdomen and thigh |
| Rash, hives or swelling beyond the injection site | Report it to your physician promptly rather than waiting; as an animal-derived protein extract it carries a theoretical allergy risk |
| Facial or throat swelling, difficulty breathing | Emergency care first (call 911), then tell your physician |
There is no established interaction list, because the trials that would produce one have not been run. Anything else acting on the immune system, such as immunosuppressants or biologics, and any autoimmune diagnosis belong on your intake. Thymalin is not used in pregnancy or breastfeeding, where safety data is absent. Tested athletes should check the current prohibited list for their sport.
Thymalin Benefits
Where thymalin stands with the FDA
Thymalin has never been nominated for the FDA's 503A bulk drug substances list. It does not appear in Category 1, 2 or 3 of the FDA's list of nominated substances, last updated on 14 May 2026; the similarly named "Thymulin acetate" on that document is a different thymic peptide. It was never in Category 2, so the removal of twelve peptides from Category 2 on 15 April 2026 did not involve it, and it was not on the Pharmacy Compounding Advisory Committee's agenda in July 2026. The FDA has expressed no view on thymalin either way. It is not approved for anything in the United States, and compounded medications are not FDA approved.
Thymalin Benefits
How Pepti supplies it
| Detail | Thymalin |
|---|---|
| Product | Thymalin, injectable |
| What is in the vial | 5 mL multi-dose vial, 1 mg/mL (5 mg thymalin) |
| Standard directions | 0.25 mL (25 units) subcutaneously once daily Monday through Friday |
| Per dose | 0.25 mg (1 mg/mL x 0.25 mL) |
| Doses per vial | 20, about four weeks |
| Format | Vial and syringe only; no pen, capsule or nasal spray |
| Price | $209/mo, all-in |
The price covers medication, physician review, refill management and shipping, with no membership fee, and Pepti does not bill insurance. Refills run every 28 days, one vial per fill. The vial arrives as a solution ready to use, with directions printed on it, sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Keep it cold, out of light, and do not freeze it. Lot test results are at /quality/lab-results. Your physician sets your directions after reviewing your intake, and your exact dose is printed on the vial.
Thymalin Benefits
Where to get thymalin prescribed
Thymalin cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes thymalin in every state except Oklahoma, plus DC Step by step: how to get thymalin prescribed online.
References
What this is based on.
References
- Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin] · Adv Gerontol (2002) · PMID 12577695
- Khavinson VKh. Peptides and Ageing · Neuro Endocrinol Lett (2002) · PMID 12374906
- Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells · Bull Exp Biol Med (2020) · PMID 33237528
- Khavinson VK, Kuznik BI, Trofimova SV, Volchkov VA, Rukavishnikova SA, Titova ON, Akhmedov TA, Trofimov AV, Potemkin VV, Magen E. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19 · Stem Cell Rev Rep (2021) · PMID 33575961
- Kuznik BI, Shapovalov KG, Smolyakov YN, Lukyanov SA, Tereshkov PP, Kazantseva LS, Linkova NS. [Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin] · Adv Gerontol (2022) · PMID 36169363
- Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line · Int J Mol Sci (2022) · PMID 35408963
- Linkova N, Khavinson V, Diatlova A, Petukhov M, Vladimirova E, Sukhareva M, Ilina A. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19 · Int J Mol Sci (2023) · PMID 37686182
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
Thymalin Benefits, answered.
A mixture of short peptides extracted from calf thymus, developed in the Soviet Union in the 1970s. Its developers describe two dipeptides, Lys-Glu and Glu-Trp, as the active components.
Research has looked at T-cell maturation and calmer inflammatory signalling in cell studies, and Russian observational work reported fewer respiratory illnesses and lower mortality in older adults. None of it comes from randomized controlled trials.
Cell studies describe it pushing blood stem cells toward mature T-cells, and a long Russian programme reported fewer respiratory infections. No controlled trial has tested whether it strengthens immunity in people.
There are human reports, but no randomized controlled trials. The main ones are a 266-person observational programme in older adults and two Russian COVID-19 hospital studies, none of which describes randomization or blinding.
The Russian programme reported lower mortality in treated groups, but without randomization or placebo that cannot be read as evidence that thymalin extends life.
No. Thymosin alpha-1 is a single synthetic sequence with international randomized trials. Thymalin is an extract with a Russian literature and no randomized trials. Pepti supplies both.
No trial has measured a timeline. The Russian programme gave courses repeated annually and measured outcomes over years, so no timeline can be promised.
Thymalin and Epithalamin, the extract Epithalon is derived from, were studied together in the Russian ageing programme. Whether any combination fits you is something your physician works out after reviewing your intake.
Mostly injection-site redness, soreness, bruising or itching. As an animal-derived extract, it carries a theoretical allergy risk, so rash, hives or swelling beyond the injection site should be reported promptly.
No. It has never been nominated for the FDA's 503A list, so the FDA has not evaluated it either way. Compounded medications are not FDA approved.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.